Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment of new tests when cases emerge. In the current Democratic Republic of the Congo outbreak, response efforts were also hindered by limited validated assays and the initial absence of an outbreak-strain isolate. Researchers now detail approaches for rapid test qualification and virologic analysis to strengthen outbreak readiness.

The German Center for Infection Research (DZIF), together with national and international collaborators, describes two complementary investigations addressing diagnostics and immunology for BDBV. One effort established a decentralized network to evaluate PCR assays during the ongoing 2026 outbreak. A second study examined host‑cell entry of the 2026 BDBV strain and assessed whether antibodies elicited by a licensed recombinant VSV‑ZEBOV Ebola vaccine can neutralize BDBV in vitro.

At Charité—Universitätsmedizin Berlin, investigators isolated BDBV genetic material from a throat swab collected from a U.S. patient admitted on May 20, 2026, and used it to create a reference standard for assay benchmarking. An international consortium of nine laboratories, including DZIF, the German National University Medicine Network (NUM), several European research consortia, major university hospitals, and biosafety level-4 (BSL-4) facilities, then evaluated four candidate PCR tests from two manufacturers. Comprehensive analytical and clinical assessments were completed within two weeks and showed no evidence of cross-reactivity.

Separately, researchers at the German Primate Center, Leibniz Institute for Primate Research, used pseudoviruses carrying glycoproteins from BDBV strains from 2007–08, 2012, and 2026 to assess cell entry and vaccine-induced neutralization. The 2026 strain did not show greater entry efficiency than earlier variants. Serum from 10 healthy volunteers who had received the licensed recombinant VSV-ZEBOV vaccine neutralized pseudoviruses carrying glycoproteins from all three BDBV strains. BDBV-specific neutralization was detected in six of 10 recipients at both 28 and 180 days, although activity was approximately 3.5–3.6 times lower than against Ebola virus.

Both studies were published this month in The Lancet Infectious Diseases. The diagnostic network shows that decentralized collaboration can generate robust performance data quickly, potentially helping to accelerate regulatory evaluation and the availability of tests for rare, high‑consequence pathogens. The authors also note that the neutralization findings were derived from pseudovirus assays and require confirmation with authentic BDBV, and they do not demonstrate protection in people. Together, the work points to the value of pre‑established laboratory networks, reference materials, and clear pathways to shorten the time from outbreak detection to reliable diagnostics and potential preventive measures.

Related Links
Charité—Universitätsmedizin Berlin
DZIF